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Abstract
Peroxisome Proliferator-Activated Receptor Gamma (PPARG) is one of the three members of the PPAR family of
transcription factors. Besides its roles in adipocyte differentiation and lipid metabolism, we recently demonstrated an
association between PPARG and metastasis in prostate cancer. In this study a functional effect of PPARG on AKT serine/
threonine kinase 3 (AKT3), which ultimately results in a more aggressive disease phenotype was identified. AKT3 has
previously been shown to regulate PPARG co-activator 1 alpha (PGC1α) localisation and function through its action on
chromosome maintenance region 1 (CRM1). AKT3 promotes PGC1α localisation to the nucleus through its inhibitory
effects on CRM1, a known nuclear export protein. Collectively our results demonstrate how PPARG over-expression drives
an increase in AKT3 levels, which in turn has the downstream effect of increasing PGC1α localisation within the nucleus,
driving mitochondrial biogenesis. Furthermore, this increase in mitochondrial mass provides higher energetic output in the
form of elevated ATP levels which may fuel the progression of the tumour cell through epithelial to mesenchymal transition
(EMT) and ultimately metastasis.
Introduction
Prostate cancer (PC) is the most common cancer in adult
males in the developed world and the second leading cause
of cancer deaths [1]. It has long been known that PC pro-
gression is dependent on androgens [2] and as such many
treatments centre around inhibition of androgens and the
androgen receptor. However, some PCs develop resistance
to these treatments, developing a “castrate resistant” state,
which ultimately results in metastasis and death [3]. It is this
cohort of patients that have the greatest unmet need, and for
which new therapies are desperately sought.
In a transposon-based Sleeping- Beauty genetic screen [4],
PPARG was identified as being expressed at elevated levels
in advanced, metastatic PC. Further analysis of prostate
tumour lysates revealed that up-regulation of PPARG cor-
related with increased levels of its downstream metabolic
effectors such as Fatty acid synthase (FASN), acetyl-CoA
carboxylase (ACC) and ATP citrate lyase (ACLY) [4, 5].
Phenotypically this was associated with increased lung and
lymph-nodes metastasis, suggesting a way of stratifying
patients with PPARG or FASN activation to targeted
treatments for their aggressive disease. In this study we
further investigate the mechanism by which PPARG drives
aggressive PC by identifying a link between PPARG and
elevated mitochondrial biogenesis through its effects on
AKT3, and PGC1α.
PGC1α is a well-known regulator of mitochondrial bio-
genesis [6] and is highly expressed in tissues where energy
demand is high [7, 8]. As its name suggests PGC1α is a co-
factor for PPARG [8], and as well as being the master
regulator for mitochondrial biogenesis, also affects the
transcription of key genes required for oxidative metabo-
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AKT3 is one of three isoforms of AKT (AKT1 &
AKT2 being the other isoforms) that regulate a number
of diverse cellular processes including metabolism,
proliferation, cell survival, growth and angiogenesis
[10]. Each isoform performs a number of distinct func-
tions that cannot be compensated for by another [11, 12].
AKT3 has been shown to affect mitochondrial mass
and function [13, 14], by influencing the localisation
of PGC1α [14], which is fundamental for its role in mito-
chondrial biogenesis [15]. Mechanistically, AKT3 affects
the stability of CRM1, the major nuclear export protein,
which exports PGC1α from the nucleus to the cytoplasm
[15].
In this study we identify a previously unknown role for
PPARG in up-regulating AKT3, which promotes PGC1α
localisation to the nucleus and consequently increases
mitochondrial mass and function, increasing ATP levels,
tumour growth and metastasis.
Methods
Orthograft prostate cancer model
For prostate orthograft animal experiments, CD1-nude male
mice were obtained from Charles River Research Models &
Services (UK) at 6–8 weeks of age and cells injected into
the anterior prostate lobes. Further details given in supple-
mentary methods.
RNA-seq
Quality of the purified RNA was tested on an Agilent 2200
Tapestation using RNA screentape. Libraries for cluster
generation and DNA sequencing were prepared following
an adapted method from Fisher et al. 2011 [16] using
Illumina TruSeq Stranded mRNA LT Kit. Quality and
quantity of the DNA libraries was assessed on an Agilent
2200 Tapestation (D1000 screentape) and Qubit (Thermo
Fisher Scientific) respectively. The libraries were run on
the Illumina Next Seq 500 using the High Output 75
cycles kit (2x36cycles, paired end reads, single index).
Quality checks on the raw RNASeq data files were done
using fastqc version 0.10.1 [17] and fastq_screen version
0.4.2 [18]. RNASeq reads were aligned to the GRCh38
[19] version of the human genome using tophat2 version
2.0.13 [20] with Bowtie version 2.4.4.0 [21]. Expression
levels were determined and statistically analysed by a
combination of HTSeq version 0.9.1 [22], the R 3.3.3
environment, utilising packages from the Bioconductor
data analysis suite and differential gene expression ana-
lysis based on the negative binomial distribution using the
DESeq2 [23].
Statistical analysis
Statistical analyses, with the exception of that described for
the RNA-seq data, was undertaken using GraphPad Prism
v8.1.1(224). The tests used comprised of un-paired two
tailed t-tests, Mann–Whitney, ratio t-test, Spearman corre-
lation and Two and One-way Anova, with post tests for
multiple comparisons (detailed in figure legends). All
experiments (with the exception of those involving mice)
were performed in biological replicates, with technical
replicates for each experiment given in the methods. For
mouse experiments six mice were used for each cell line
derived clone. For technical reasons only five mice were
available at endpoint for mice from the KO1 and KO2
cohorts.
Results
PPARG is required for in vivo tumour growth
Using the established PC cell lines DU145 and PC3-M,
stable cell lines exhibiting over-expression or knockout of
PPARG were generated. In PC3-M cells, which express
high endogenous levels of PPARG [4], knockdown of
PPARG was achieved using CRISPR/CAS9 technology.
Three clones were selected, two with almost complete
knockdown of PPARG (KO1 and KO2) and one with
partial knockdown (KO8) in addition to the non-targeting
control (NTS), verified by immunoblot and qPCR (Fig. 1A, B).
CD1 nude mice were orthotopically implanted with PC3-M
PPARG KO clones and NTS control into the anterior
prostates of male mice. Mice implanted with NTS control
produced tumours that were significantly bigger than those
from KO clones (Fig. 1C, D). Mice implanted with KO
clones produced very small or no tumour at all. Immuno-
histochemistry (IHC) analysis on those KO tumours that did
develop showed that all expressed PPARG (Fig. 1E and
Supplementary Fig. 1A). In addition the levels of Ki67,
indicating proliferating cells, and downstream effector of
PPARG, FASN [24], were also similar to NTS control in
these tumours, with FASN expression levels correlating
with PPARG (Supplementary Fig. 1B–D). The PPARG
CRISPR construct used to generate the clones also con-
tained the gene for red fluorescent protein (RFP), thus IHC
for RFP could be used to determine if the tumours that had
developed had derived from cells still expressing this con-
struct. None of the tumours derived from KO1, 2 and 8
implanted cells expressed RFP (Supplementary Fig. 1E).
Furthermore RNA-scope in situ hybridisation for human
peptidyl Isomerase B (HuPPIB), demonstrated detectable
levels in the NTS and all K0 tumours (Supplementary
Fig. 1F, G), suggesting that in the tumours arose from a
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small sub-population of human cells that were not knocked
down for PPARG. This would also account for the reduced
size of the tumours in the KO1, 2 and 8 at endpoint as
compared to control (NTS), as they would have smaller
starting population at point of injection.
DU145 cells, which express low endogenous levels of
PPARG [4], were transfected with a plasmid construct to
induce constitutive PPARG over-expression (OE). Three
clones were chosen, two with higher levels of PPARG as
evidenced by qPCR (OE12 and OE18) and one with ele-
vated levels of PPARG detectable by both qPCR and
immunoblot (OE19), and an empty vector control (EV7)
(Fig. 1F, G). CD1 nude mice were implanted with these
clones of OE and EV7 control. Five out of six mice
implanted with clone OE19, the clone expressing the
highest level of PPARG, generated tumours. These tumours
were all significantly bigger than those generated from the
EV7 control (Fig. 1H, I). Clones OE12 and OE18,
expressing intermediate levels of PPARG, produced
tumours ranging in size between that of the EV7 and OE19
clones (Fig. 1H, I). IHC analysis demonstrated, elevated
Ki67 expression (Supplementary Fig. 1H, I), and PPARG in
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all tumours derived from the OE clones as compared to
EV7. FASN levels were also significantly elevated in clones
OE18 and OE19 as compared to EV7 and observed to
correlate with the increased PPARG levels (Fig. 1J, K and
Supplementary Fig. 1J).
Together this data suggests an increase in proliferation
and lipid metabolism regulated by PPARG, as previously
observed [4]. There appears to be a requirement for
PPARG in tumour growth and development in vivo, as no
PPARG negative tumours developed, it suggests that not
only is PPARG able to accelerate tumour growth and
development, but it may be essential for the tumour
establishment.
Metabolic effects of PPARG in prostate cancer
FASN, a downstream effector of PPARG [24], was elevated
in OE orthotopic tumour samples (Fig. 1J, K), suggesting a
metabolic effect of PPARG. To further investigate this
Seahorse bioscience stress test assays, measuring cellular
oxygen consumption, were performed.
PC3-M KO clones demonstrated a significantly reduced
oxygen consumption rate (OCR), for all three KO clones as
compared to NTS control, with KO1 and KO2 being sig-
nificantly different to NTS in all phases of the assay
(Fig. 2A, B). Furthermore, there appeared to be a “dose”
dependent effect of PPARG on OCR. The partial knock-
down clone KO8 displayed an OCR between that of the
NTS control (on average 20% less than NTS) and complete
knockouts KO1 and KO2 which had even lower OCR (on
average 50% less than NTS). The DU145 PPARG over-
expressing (OE) cells revealed no reciprocal advantage with
increased PPARG levels (Fig. 2C, D).
A change in OCR results from differences in mito-
chondrial function and/or mass. Therefore, IHC was per-
formed on the OE and EV7 derived tumours for VDAC1, a
mitochondrial voltage dependant anion channel, used here
as a surrogate measure for mitochondrial mass (Fig. 2E). It
was observed that VDAC1 was significantly elevated in
OE18 and OE19 as compared to EV7 (Fig. 2F), indicating
an increase in mitochondrial mass. To determine if this
increased mass was affecting metabolic output 13C labelled
glucose metabolomics was performed on OE cells grown in
3D spheroid culture. A significant increase in ATP was
observed in the OE19 clones as compared to EV7 (Fig. 2G),
indicating elevated energy output concurrent with the ele-
vated mitochondrial mass observed. To find the link
between elevated mitochondrial mass, ATP production and
PPARG; RNA-Seq (of orthograft samples) was undertaken
(using De-Seq2 method, details in material and methods).
From this we identified the top ten significant hits (Fig. 2H,
full list given in Supplementary Fig. 2A). Within the top
ten, and with a fold change of 1.8 and −7.3 for EV7 vs
OE19 and NTS vs K02 respectively, AKT3 appeared an
interesting candidate given its presumptive role in mito-
chondrial biogenesis through CRM1 and PGC1α and
metabolism [13–15, 25]. This result was validated by RNA-
scope in situ hybridisation confirming statistically sig-
nificant elevated AKT3 mRNA expression in DU145 OE
tumours, compared to EV7 tumours (Fig. 2I, J). Interest-
ingly, given initial immunoblotting for PPARG (Fig. 1A,
F), AKT3 levels appeared higher in OE19 as compared to
NTS. When PPARG expression from in vivo experiments is
compared, it does in fact appear that OE19 tumours have
significantly higher PPARG expression than NTS tumours,
which could account for the elevated AKT3 levels observed
in OE19 tumours (Supplementary Fig. 1K).
Further validation of PPARG’s effect on this pathway
was established through immunoblot of tumour lysates
probing for PPARG, AKT3, PGC1α, CRM1 and VDAC1
(Fig. 2K and Supplementary Fig. 2B, C). Tumours derived
Fig. 1 PPARG expression is necessary for tumour development
in vivo. A Immunoblot of PC3-M CRISPR knockdown of PPARG
clones (KO1, 2 & 8) and Scrambled control (Scrm), representative
image of three experiments. Values above each band indicate densi-
tometry value of band as normalised to Actin loading control and
compared to first band (NTS), N.D not detected. B qPCR analysis for
PPARG levels in clones KO1, 2 & 8, and control Scrm, three inde-
pendent experiments and three technical replicates per experiment,
error bars show SEM. C Ultrasound measurement of tumour size (KO
clones & Scrm control) over time in days, ‘*’ denotes statistical sig-
nificance p ≤ 0.05 as determined by 2-way Anova and Dunnett’s
multiple comparison test. D Final tumour weight (KO clones & Scrm
control) upon necropsy, ‘*’ denotes statistical significance p ≤ 0.05 as
determined by one-way Anova and Holm-Sidaks multiple comparison
test. For both C and D graphs represent 23 mice, at least 5 mice per
cell line; ultrasound performed every two weeks until endpoint. All
mice taken at the same time when the first mouse reached
endpoint. E IHC images of PPARG KO derived orthograft tumours.
Representative images from PPARG KO tumours stained for PPARG
and FASN, scale bar shows 100 μm. F Immunoblot of DU145 PPARG
over-expressing clones (OE12, 18 & 19) and control (EV7), repre-
sentative image of three independent experiments. Values above each
band indicate densitometry value of band as normalised to Actin
loading control and compared to first band (EV7), N.D not detected. G
qPCR analysis for PPARG levels in OE12, 18 & 19 and control EV7
qPCR three independent experiments and three technical replicates per
experiment, error bars show SEM. H Ultrasound measurement of
tumour size over days in OE clones & EV7 control, statistical sig-
nificance is denoted by * where p ≤ 0.05 as determined by 2-way
Anova and Dunnetts multiple comparison test. I Final tumour weight
upon necropsy in OE clones & EV7 control. Statistical significance is
denoted by * where p ≤ 0.05 determined by one-way Anova and Holm-
Sidak’s multiple comparisons test. For H and I graphs represent 24
mice, 6 mice per cell line, ultrasound performed every two weeks until
endpoint. All mice were taken at the same time when the first mouse
reached endpoint. J IHC images of PPARG OE derived orthograft
tumours. Representative images from tumours stained for PPARG and
FASN, scale bar shows 100 μm. K IHC image analysis for PPARG
and FASN. Graph displays average percentage positive cells over at
least three samples per clone with error bars giving SEM. Statistical
significance, where found, denoted by * with p ≤ 0.05 determined by
Mann–Whitney.
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from clone OE19 showed elevated AKT3, PGC1a and
VDAC1 confirming the effect of PPARG on this pathway.
These results were also observed for OE12 and OE18 but
only in some samples and were not consistent. For OE19
most of the prostate was composed of tumour tissue, whilst
for OE12 and OE18 the tumours were smaller, with only a
portion of the prostate composed of tumour tissue. The rest
was found to be histologically normal which may account
for the variability in the protein levels shown on the
immunoblot compared to IHC, where lysates derive from
pulverised prostate containing both tumour and potentially
normal tissue.
Tumour samples were also probed by immunoblot for
each complex in the Electron Transport Chain (ETC)
(Fig. 2L and Supplementary Fig. 2C). Again, in clone OE19
each of these complexes were found to be increased as
compared to EV7, with the exception of Complex V. As
before the results for OE12 and OE18 were mixed. These
changes are concurrent with the effect of PPARG on the
AKT3-CRM1-PGC1α pathway as PGC1α in addition to its
role in mitochondrial biogenesis also regulates the expres-
sion of the ETC complexes [9].
Together this suggests elevated PPARG levels induce
increased expression of AKT3, which, given its established
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functional link to PGC1α and mitochondrial biogenesis [15]
would explain the increased mitochondrial mass and ATP
levels observed upon PPARG over-expression. This
increase in ATP levels may fuel the increase in growth and
metastasis observed upon increased levels of PPARG.
PPARG contributes to epithelial to mesenchymal
transformation
When culturing the KO and OE clones in 2D conditions no
obvious effects of altered PPARG expression were observed,
however striking differences were observed when growing
them as 3D spheroids. The EV7 clones grew as uniform
rounded spheroids (referred to as spheres), whilst the OE19
clones grew in a much less uniform fashion with cells pro-
truding from the main sphere, (referred to as projections)
(Fig. 3A). The percentage of sphere and projection spheroid
type was quantified showing a significant difference in the
number of spheres versus projections when comparing EV7
to OE19 clones (Fig. 3B). This type of spheroid morphology
is suggestive of loss of cellular polarity, a key feature of
epithelial to mesenchymal transition (EMT), which is pro-
posed to be required for successful metastasis to occur [26].
Immunoblotting was performed with spheroid lysates and
AKT3, VDAC1, all the complexes of the ETC, and EMT
markers N-Cadherin and Vimentin were found to be elevated
in OE19 as compared to EV7, (Fig. 3C and Supplementary
Fig. 3A). In the OE12 and OE18 clones little or no projections
were observed, however, a difference in the size of the
spheres was noted. We quantified this and found that both
OE12 and OE18 produced significantly bigger spheres than
EV7 cells (Supplementary Fig. 3B, C). This increase in
spheroid size is indicative of a growth advantage in these
PPARG OE cells in 3D as compared to EV7. Immunoblotting
of these spheroids showed a similar elevation in all proteins of
interest in OE18 compared to EV7, however OE12 showed
mixed results (Supplementary Fig. 3A, D). The less dramatic
observations likely result from the expression level of PPARG
in these clones as compared to OE19.
To understand the possible connection to the PPARG-
AKT3 functional axis we knocked-down AKT3 using
siRNA (Fig. 3D–F). EV7 cells were unaffected whilst OE19
cells appeared to show a partial reversion back to the sphere
phenotype (Fig. 3D). Upon quantification this partial
reversion was found to be significant (Fig. 3E), implying the
projections phenotype was affected by AKT3. Furthermore,
immunoblot analysis of the lysates demonstrated the effect
of AKT3 loss on mitochondrial mass as evidenced by
decreased expression of VDAC1 and the ETC complexes
(Fig. 3F). This indicates that in 3D AKT3 is at least partially
responsible for the effects observed.
Treating the spheroids with PPARG inhibitor GW9662
or knockdown with PPARG specific siRNA, showed
greater reversion than knockdown of AKT3. EV7 cells were
unaffected by PPARG inhibition or knockdown, however
OE19 cells showed reversion to the sphere phenotype
(Fig. 3G and Supplementary Fig. 3E, F), following quan-
tification this was shown to be statistically significant (Fig.
3H and Supplementary Fig. 3G). Immunoblot analysis of
lysates derived from these treated 3D cultures revealed that
as well as VDAC1 and the proteins of the ETC complexes
being reduced upon PPARG inhibition so was AKT3
(Fig. 3I and Supplementary Fig. 3H).
This further demonstrates the link between AKT3 and
PPARG and their downstream effects on mitochondrial mass
and energy output potentially facilitating EMT progression.
Fig. 2 Mitchondiral effects of PPARG lead to identification of
AKT3 as a novel PPARG effector gene. A, B Seahorse Bioscience
mito stress test assay KO clones & Scrm control, graphs represent
three independent experiments and four technical replicates per
experiment, error bars show SEM. Statistical significance denoted by *
where p ≤ 0.05 determined by 2-way Anova and Dunnetts multiple
comparison test. C, D Seahorse Bioscience mito stress test assay OE
clones & EV7 control, graphs represent three independent experiments
and four technical replicates per experiment, error bars show SEM.
Statistical significance denoted by * where p ≤ 0.05 by 2-way Anova
and Dunnetts multiple comparison test. E IHC representative images
for VDAC1 staining in OE & EV7 derived tumours, scale bar repre-
sents 100 μm. F Analysis of IHC images for VDAC1. Graph displays
average percentage of positively stained cells over at least three
samples with error bars giving SEM. Statistical significance, where
found, denoted by * with p ≤ 0.05 determined by Mann–Whitney. G
Carbon 13 labelled glucose derived ATP levels from EV7 and OE19
clones grown in 3D, unlabelled not shown. Represents three inde-
pendent experiments each with three technical replicates. Bars repre-
sent average of these experiments with error bars showing SEM.
Statistical significance is denoted by * where p ≤ 0.05 determined by 2
way Anova and Sidak’s multiple comparisons test where +5 ATP was
highlighted as the significantly different isotopologue. H Subset of top
10 significant hits from RNA-seq analysis performed on tumour
samples derived from PC3-M Scrm control, KO2, and DU-145 EV7
and OE19 clones. Three tumour samples from each cell type were
used. Scrm vs. KO2 compared to EV7 vs. OE19 to identify hits that
were oppositely affected in each comparison. All hits are statistically
significant with p ≤ 0.05 and are ordered in terms of statistical sig-
nificance, further details of analysis are given in the material and
methods section. I RNA-scope in situ hybridisation representative
images for AKT3 probing in OE & EV7 derived tumours, scale bar
represents 50 μm. J Halo software analysis of RNA-scope for AKT3
on tumours derived from OE cell lines. Analysis performed on at least
three prostate samples for each cell type used, graph displays average
with error bars giving SEM. Statistical significance denoted with *
where p ≤ 0.05 determined by Anova and Dunnett’s multiple com-
parisons test. K Immunoblot analysis from EV7 and OE19 derived
tumour samples, three tumours per cell type. Values above each band
indicate the densitometry value of the band as normalised to the
loading control HSC70 and compared to the first EV7 band. Probed for
PGC1a, CRM1, AKT3 and VDAC1, image representative of three
independent experiments. L Immunoblot for the ETC complexes,
complex I is labelled in blue and complex IV in red to allow the reader
to identify the correct densitometry value for the corresponding bands,
image representative of three independent experiments. Values above
each band indicate the densitometry value of the band as normalised to
the loading control HSC70 and compared to the first EV7 band.
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Fig. 3 Phenotypic effects of PPARG over-expression in 3D culture
regulated by the PPARG-AKT3 functional axis. A Characterisation
of the phenotypic effect of PPARG over-expression in 3D culture
representative images of EV7 and OE19 cells grown in 3D, images
representative of three independent experiments. B Quantification of
the two different spheroid appearances, represents three independent
experiments and eight technical replicates per experiment. error bars
show SEM Statistical significance denoted by *p ≤ 0.05 determined by
2-way Anova and Sidak’s multiple comparisons test. C Immunoblot
analysis from 3D spheroids of EV7 and OE19 for mitochondrial ETC
complexes, AKT3, CRM1 and VDAC1. HSC70 was used as loading
control. Values above each band indicate the densitometry value of the
band as normalised to the loading control HSC70 and compared to the
EV7 band. Complex I is labelled in blue and complex IV in red to
allow the reader to identify the correct densitometry value for the
corresponding bands, image representative of three independent
experiments. D siRNA knockdown of AKT3 effect in 3D culture
appearance on EV7 and OE19 cells grown in 3D either treated with
non-targeting siRNA (siNTS) or AKT3 targeting siRNA (siAKT3).
Images representative of three independent experiments. E Quantifi-
cation of the two different spheroid appearances following AKT3
knockdown, represents three independent experiments and ten tech-
nical replicates per experiment, error bars show SEM, Statistical sig-
nificance denoted by *p ≤ 0.05 determined by 2-way Anova and
Sidak’s multiple comparisons test. F Immunoblot analysis from lysates
derived from 3D siRNA knockdown of AKT3, showing the ETC
complexes, VDAC1 and AKT3. HSC70 was used for loading control.
Complex I is labelled in blue and complex IV in red to allow the reader
to identify the correct densitometry value for the corresponding bands,
image representative of three independent experiments. Values above
each band indicate the densitometry value of the band as normalised to
the loading control HSC70 and compared to EV7 siNTS. G PPARG
inhibitor effect on 3D spheroid appearance. EV7 and OE19 cells
grown in 3D either treated with DMSO or PPARG inhibitor GW9662
at 20 μM. Images representative of three independent experiments.
H Quantification of the two different spheroid appearances following
GW9662 treatment, represents three independent experiments and ten
technical replicates per experiment, error bars show SEM, Statistical
significance denoted by *p ≤ 0.05 determined by 2-way Anova and
Sidak’s multiple comparisons test. I Immnuoblot analysis from lysates
derived from 3D spheroid treatment with PPARG inhibitor GW9662 at
20 μM, showing the ETC complexes, VDAC1 and AKT3. HSC70 was
used for loading control. Complex I is labelled in blue and complex IV
in red to allow the reader to identify the correct densitometry value for
the corresponding bands, image representative of three independent
experiments. Values above each band indicate the densitometry value
of the band as normalised to the loading control HSC70 and compared
to EV7 DMSO.
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PPARG alters PGC1α localisation and function
through AKT3
AKT3 has been shown to increase mitochondrial biogenesis
through blocking PGC1α export from the nucleus via
CRM1 [15]. It should be noted that the localisation of
PGC1α within the cell rather than just the absolute
abundance is important to its functionality [15]. Using
immunofluorescence (IF) it is possible to observe PGC1α
localisation within the cells of 3D spheroids and quantify
this (Fig. 4A, B and Supplementary Fig. 3I), revealing that
OE19 spheroids display a higher nuclear to cytoplasmic
ratio of PGC1α than the EV7 control (Fig. 4B). To deter-
mine if this effect was truly dependent on AKT3, the
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experiment was repeated with knock down of AKT3 with
siRNA (Fig. 4C, D and Supplementary Fig. 3J). Knock-
down of AKT3 resulted in a loss of total PGC1α in both
EV7 and OE19 (Fig. 4D). For EV7 this total loss did not
affect the nuclear to cytoplasmic ratio, however for OE19
there appeared to be a shift from nuclear localisation to
cytoplasmic (Supplementary Fig. 3J). This is consistent
with increased CRM1 function resulting from loss of
AKT3 suppression and consequently greater PGC1a export
from the nucleus.
However, when examining the levels of CRM1 in
tumour samples and spheroid lysates we observed that
CRM1 levels appeared similar or higher in OE19 samples
as compared to EV7 control (Figs. 2K and 3C). IHC ana-
lysis was performed for CRM1 on the tumours, which
showed reduced nuclear CRM1 levels in the all OE clones
as compared to EV7 derived tumours (Fig. 4E, F). AKT3’s
regulation of CRM1 is through its ability to inhibit its
function through phosphorylation of the CRM1 protein,
inducing its degradation [15]. Such regulation may not
affect the total level of protein but still affect functionality.
To investigate this IF analysis of 3D spheroid cultures was
performed (Fig. 4G), with the localisation of the CRM1
found to be altered in OE19 as compared to EV7. In the
OE19 clones, cytoplasmic aggregates of CRM1 were
observed, which were absent in the EV7 spheres, altering
the nuclear to cytoplasmic ratio for CRM1 significantly
(Fig. 4H). Although total CRM1 levels may not change, or
may indeed increase, its location is altered, reducing its
nuclear export function.
Furthermore, upon cycloheximide block of translation
for twenty four hours, the known half-life of CRM1 [27], a
dramatic reduction in CRM1 levels in the OE clones as
compared to EV7 is observed (Fig. 4I and Supplementary
Fig. 3K). This suggests that degradation of CRM1 is ele-
vated in the OE clones, but the rate of protein production is
high enough that the total level of protein appears unaf-
fected or even elevated, whilst its localisation and thereby
function is significantly altered.
PPARG through AKT3 is able to increase the nuclear
levels of PGC1a, by disrupting the stability of nuclear
export protein CRM1. AKT3 reduces the stability of CRM1
and its nuclear localisation, preventing its function and
ensuring PGC1α remains in the nucleus. With increased
nuclear PGC1α mitochondrial biogenesis and ETC complex
levels are increased, which allows for the increase in ATP
observed (Fig. 2G), fuelling growth and metastasis. When
PPARG levels fall, the reverse is true, resulting in mito-
chondrial dysfunction [12–15, 25] and reduced ATP levels
(Fig. 4J).
Discussion
We have previously identified PPARG as a potential target
in metastatic PC [4]. In this work we have been able to
identify a novel effector of PPARG, AKT3, which elicits its
effects through the AKT3-PGC1α axis. PPARG, tradition-
ally thought as a regulator of lipid metabolism, was
observed to up-regulate AKT3 which de-stabilises CRM1
increasing PGC1α retention in the nucleus. This leads to
increased mitochondrial biogenesis and ETC levels. Con-
sequently, ATP levels are elevated likely providing for the
increased energetic demands of tumour growth and
metastasis.
It appears that the role of PPARG within the prostate
tumour environment is critical for survival within the
in vivo system due to the inherent pressures and stresses of
the tumour environment. Tumours lacking any PPARG
expression fail to develop, and any tumours that do develop
express PPARG (Fig. 1 and Supplementary Fig. 1). This
would suggest that the tumour environment exerts a selec-
tive pressure on the tumour cells favouring those that
Fig. 4 PPARG prevents PGC1α nuclear export by disrupting the
stability of CRM1 through AKT3 up-regulation, and so increases
mitochondrial biogenesis & function. A Immunofluorescence of 3D
spheroids, representative images for EV7 and OE19 clones grown in
3D, fixed and stained for the nuclear stain DAPI (Blue), PGC1α/Alexa
555 (Red) and Cell volume with cell mask (green). B PGC1α nuclear
to cytoplasmic ratio, determined through Volocity image analysis.
Represents four independent experiments and six images from each
experiment, bars represent average over these experiments and error
bars the SEM. Statistical significance is denoted by * where p ≤ 0.05
determined by Mann–Whitney. C Immunofluorescence 3D spheroids
with siRNA knockdown of AKT3, representative images for EV7 and
OE19 clones grown in 3D, fixed and stained for the nuclear stain DAPI
(Blue), PGC1α/Alexa 555 (Red) and Cell volume with cell mask
(green). D Quantification of total PGC1a levels by IF following
knockdown of AKT3 by siRNA in 3D culture in EV7 and OE19
clones, normalised to cell number. Three independent experiments five
images per experiment. Bars represent average over these experiments
and error bars the SEM. Statistical significance is denoted by * where
p ≤ 0.05 determined by Mann–Whitney. E IHC representative images
for CRM1 staining in OE and EV7 derived tumours, scale bar repre-
sents 100 μm. F Analysis of IHC images for CRM1. Graph displays
average percentage of positively stained cells over at least three
samples with error bars giving SEM. Statistical significance, where
found, denoted by * with p ≤ 0.05 determined by Mann–Whitney. G
Immunofluorescence of 3D spheroids, representative images for EV7
and OE19 clones grown in 3D, fixed and stained for the nuclear stain
DAPI (Blue), CRM1/Alexa 555 (Red) and Cell volume with cell mask
(green). H CRM1 nuclear to cytoplasmic ratio, determined through
Volocity image analysis. Represents three independent experiments
and five images from each experiment, bars represent average over
these experiments and error bars the SEM. Statistical significance is
denoted by * where p ≤ 0.05 determined by Mann–Whitney.
I Immunoblot analysis of 3D spheroids grown in the presence or
absence of cyclohexamide. Probed for CRM1 with loading control
HSC70, image representative of three independent experiments.
J Schematic outlining hypothesis for PPARG effect on: AKT3,
PGC1α and mitochondrial biogenesis.
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express PPARG. The KO1 and KO2 cell lines in vitro
express no PPARG (Fig. 1A), yet in vivo expressed
equivalent levels to the NTS control (Fig. 1E and Supple-
mentary Fig. 1A). A similar effect was observed in the OE
clones, where EV7 developed a few small tumours, yet once
again all of these were PPARG positive. During the same
time period clone OE19 was able to develop end-point
tumours in all but one mouse, clearly indicating a require-
ment for PPARG for in vivo prostate tumour development.
Seahorse stress test assays identified a reduced mitochon-
drial function in the PC3-M KO cells when PPARG levels
were reduced, yet, DU145 OE clones showed no differences
in OCR. This was also true for a number of 2D in vitro
assays performed (data not shown) for both DU145 OE and
PC3-M KO cells, suggesting optimal growth conditions in
2D culture are not sufficiently representative of the stresses
of the in vivo environment for the advantages of PPARG
expression to be evidenced. Seahorse assays provide a
slightly elevated level of stress due to the reduced serum
concentration required, which may account for the observed
effect in the PC3-M KO cells, yet this level of stress was not
sufficient to demonstrate the effects of PPARG over-
expression in DU145 cells. PPARG only appears to become
functionally essential in vivo and in 3D culture conditions,
which are more physiologically relevant.
The FASN (Fig. 1E, J, K and Supplementary Fig. 1C, D,
J) and Seahorse data suggested a metabolic effect of
PPARG, which influenced mitochondrial mass (Fig. 2E, F,
K) and ATP levels (Fig. 2G). Given the known function of
PPARG we anticipated this would result from up-regulation
of genes involved in lipid metabolism. Surprisingly data
from RNA-Seq of the tumour samples identified AKT3
(Fig. 2H) as a novel target of PPARG and the probable link
between PPARG and the observed changes at the mito-
chondrial level given the known role of AKT3 in PGC1a
regulation and mitochondrial biogenesis [14, 15, 25].
Indeed, using the eukaryotic promotor database two
PPARG binding motifs are predicted within the AKT3 gene
promotor, suggesting a possible mode of action for PPARG
on AKT3 [28]. There are many regulators of AKT3;
including VEGF, PDGF and IGF1, which may also play a
role in AKT3’s function in PC, perhaps either in addition to
or in synergy with PPARG and provide interesting avenues
for future investigation [14, 29–31].
Growing the OE clones as spheroids highlighted a very
striking phenotypic differences between the OE clones and
their EV7 control, suggestive of a loss of cellular polarity,
reminiscent of an EMT like phenotype (Fig. 3A, B and
Supplementary Fig. 2G). Knockdown of AKT3 reduced this
effect significantly, but not completely (Fig. 3D–F), sug-
gesting perhaps in addition to its role in the AKT3/PGC1α
pathway PPARG may also be affecting other pathways.
This is supported by the data from the PPARG inhibitor and
siRNA studies showing a more pronounced reversion of
phenotype (Fig. 3G–I and Supplementary Fig. 2H–K). As
the inhibitor and siRNA are acting on PPARG and therefore
upstream of AKT3 it not only reduces PPARG’s effect on
AKT3 but also on any other potential downstream effectors,
resulting in the more pronounced effect
PPARG is a ligand activated nuclear receptor known for
its roles in adipocyte differentiation and lipid metabolism.
Its activity is governed by ligand binding, cellular locali-
sation and post translational modifications the latter
appearing to have an inhibitory role [32–34]. In our hands
its activity was evidenced through increases in downstream
effectors of lipid metabolism (Fig. 1E, J, K and Supple-
mentary Fig. 1C, D, J) [4]. These lipogenic enzymes are
observed by others to be regulated in a PGC1α dependant
pro-tumourgenic manner [35]. Therefore, it is possible that
these additional functional effects of PPARG and PGC1a
are, along with PPARG’s ability to increase exogenous fatty
acid uptake [36, 37], synergistic with the mitochondrial
biogenesis effects of PPARG, and could account for some
additional functions of PPARG in prostate cancer not
attributable to AKT3.
The effect of PPARG driven AKT3 up-regulation results
in an accumulation of PGC1α (Fig. 2K), which drives
mitochondrial biogenesis and tumour growth and develop-
ment [7, 8]. This appears to be at odds with the work from
previously published studies [38, 39], which describe how
PGC1α can supress PC metastasis and aggressiveness. In
the Torrano et al. study PGC1α up-regulation drives
oestrogen-related receptor alpha (ERRα) target gene tran-
scription instigating a metabolic switch to a catabolic pro-
gram, which inhibits PC progression [38]. This effect is
almost completely dependent upon the transcription factor
ERRα, a PGC1α co-factor. Similarly, the Kaminski et al.
study links PGC1α’s suppressive effects to ERRα and c-
Myc and downstream polyamine synthesis [39]. However,
PGC1α is a co-activator for numerous transcription factors,
such as PPARG and the other PPAR’s (alpha and beta), as
well as ERR alpha, beta and gamma, Fox01, hepatocyte
nuclear factor 4α (HNF4α) and nuclear respiratory factor 1
(NRF1) [6, 8, 40–44]. Notably both these studies [38, 39]
focus on the PGC1α/ERRa relationship and the subset of
genes they regulate as the cause of PGC1α suppression of
metastasis. The PPARs and ERRs (with PGC1α) are known
to regulate different gene sets [40] and perhaps it is this
difference in the genes transcribed that determines if PGC1a
is pro or anti-tumour progression. Where PPARG levels are
high, as in our case, perhaps it is the effect of PGC1α rather
than ERRα which is determining the gene signature.
Indeed, examining PGC1α levels in vivo by immunoblot
revealed it to be elevated in OE tumours. IF analysis of 3D
spheroids showed the nuclear localisation of PGC1a to be
similarly affected (Fig. 4A, B). This effect appeared to be
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lost upon knockdown of AKT3, which may explain the
phenotypic effects observed on spheroid growth upon
AKT3 knockdown observed earlier (Fig. 4C, D). CRM1
however, initially appeared to contradict the hypothesis. For
PGC1α to remain nuclear a reduction in CRM1 levels was
anticipated in conjunction with the increased AKT3 func-
tion driven by PPARG.
The action of AKT3 upon the major nuclear export
protein CRM1, affects the subcellular localisation of
PGC1α. Given AKT3’s classification as a Serine/Threonine
Kinase, it is suggested its effects on CRM1 could be via
phosphorylation [15, 45]. Indeed serine 1054 of CRM1 was
identified as crucial to AKT3’s ability to inhibit CRM1 [15],
however no evidence of AKT3 directly phosphorylating this
site has yet been observed. IHC analysis for CRM1 showed
significantly reduced CRM1 levels in OE18 and OE19
(Fig. 4E, F), but immunoblotting did not appear to reflect
this (Figs. 2K and 3C). Performing IF for CRM1 on the 3D
spheroids (Fig. 4G, H) demonstrated large non-nuclear
aggregates of CRM1 were present in clone OE19 and not in
EV7. For CRM1 to export PGC1a from the nucleus it must
be localised to the nucleus. The presence of these aggre-
gates’ accounts for the lack of change in CRM1 levels
whilst allowing for PGC1α to remain in the nucleus at a
higher level than in EV7 cells. Blocking translation using
cycloheximide, confirmed that indeed in the OE clones
CRM1 was being degraded at an elevated rate (Fig. 4I),
suggesting that PPARG through AKT3 affects the stability,
and consequently function of the CRM1 protein and thereby
retention of PGC1α in the nucleus.
Here we provide evidence for a previously unidentified
functional link between PPARG-AKT3-PGC1a, mitochon-
drial biogenesis and mitochondrial output (Fig. 4J). This
function of PPARG allows for the provision of energy
(ATP) which may fuel tumour growth and progression in
PC. The failure of PPARG negative tumours to develop
suggests that PPARG is essential for tumour growth and
progression in vivo. This absolute requirement for PPARG
highlights its crucial role in PC development, suggesting
that targeted therapies against PPARG could prove to be a
highly efficient avenue for treatment of advanced PC.
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